Replimune Group reports Q2 EPS (46c), consensus (44c)

Reports as of September 30, 2020, cash, cash equivalents and short-term investments were $244.6M, as compared to $168.6M as of March 31, 2020. This increase was primarily related to $109.5M in net proceeds from financing activities offset by cash utilized in operating activities largely associated with advancing its expanded clinical development plan. "In October, we released clinical data with our second product candidate, RP2, demonstrating durable single agent responses in heavily pre-treated patients with immune insensitive tumor types that provides validation of our platform. We also presented updated data for RP1 in combination with Opdivo in melanoma and non-melanoma skin cancers that continues to improve upon our recent June update in terms of depth and durability of response, and supports our two registration-directed clinical programs in both cutaneous squamous cell carcinoma and anti-PD1 failed melanoma. Following a successful follow-on offering in October, we are well-financed to advance and expand our pipeline of product candidates and to fund the initial build of our commercial infrastructure with many exciting milestones ahead. In particular, we look forward to initiating clinical development with RP3 as we seek to establish our products more broadly beyond immune-responsive tumor types, as a cornerstone of immune-based cancer treatments," said Philip Astley-Sparke, CEO of Replimune.